Neoleukin Therapeutics Announces Appointment of Robert K. Ho as Chief Financial Officer
25 févr. 2020 08h00 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics to Present at Cowen and Company 40th Annual Health Care Conference
24 févr. 2020 08h00 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks Idea Forum | Oncology Day
06 févr. 2020 08h00 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
20 déc. 2019 16h01 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Announces Pricing of $75.0 Million Public Offering
17 déc. 2019 22h26 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Announces Proposed Public Offering of Common Stock
17 déc. 2019 16h38 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Announces Scientific Advisory Board
05 déc. 2019 08h00 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
Neoleukin Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference
26 nov. 2019 08h00 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
Neoleukin Therapeutics Announces Corporate Update and Third Quarter 2019 Financial Results
13 nov. 2019 09h15 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, Wash., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Announces Additions to Management Team
19 sept. 2019 08h00 HE
|
Neoleukin Therapeutics, Inc.
Leslie Aberman, Vice President, Legal Affairs and Intellectual PropertySamantha Willing, Vice President, People SEATTLE, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc....